F. Ravandi Kashani

614 total citations
17 papers, 497 citations indexed

About

F. Ravandi Kashani is a scholar working on Molecular Biology, Hematology and Physiology. According to data from OpenAlex, F. Ravandi Kashani has authored 17 papers receiving a total of 497 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Hematology and 4 papers in Physiology. Recurrent topics in F. Ravandi Kashani's work include Acute Myeloid Leukemia Research (5 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Nitric Oxide and Endothelin Effects (3 papers). F. Ravandi Kashani is often cited by papers focused on Acute Myeloid Leukemia Research (5 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Nitric Oxide and Endothelin Effects (3 papers). F. Ravandi Kashani collaborates with scholars based in Germany, France and United States. F. Ravandi Kashani's co-authors include Sebastian Steven, Siyer Roohani, Thomas Münzel, Andreas Daiber, Matthias Oelze, Swenja Kröller‐Schön, Maximilian Kopp, Philip Wenzel, Eberhard Schulz and Alina Hanf and has published in prestigious journals such as Journal of Clinical Oncology, Free Radical Biology and Medicine and International Journal of Molecular Sciences.

In The Last Decade

F. Ravandi Kashani

16 papers receiving 483 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F. Ravandi Kashani Germany 9 230 161 129 83 61 17 497
Leonardo Gómez Rosso Argentina 15 196 0.9× 117 0.7× 135 1.0× 80 1.0× 67 1.1× 39 565
Shenghua Yang China 14 98 0.4× 190 1.2× 138 1.1× 84 1.0× 67 1.1× 25 536
Tomoe Kinoshita Japan 12 301 1.3× 223 1.4× 134 1.0× 44 0.5× 58 1.0× 34 592
Abdolrahim Nikzamir Iran 15 149 0.6× 141 0.9× 67 0.5× 152 1.8× 53 0.9× 54 639
Leena E. Viiri Finland 16 69 0.3× 225 1.4× 144 1.1× 143 1.7× 44 0.7× 30 574
S. Takami Japan 11 186 0.8× 146 0.9× 93 0.7× 204 2.5× 43 0.7× 12 513
Keiichi Torimoto Japan 14 441 1.9× 163 1.0× 167 1.3× 149 1.8× 76 1.2× 58 777
Mizuko Osaka Japan 13 91 0.4× 214 1.3× 96 0.7× 83 1.0× 120 2.0× 23 688
Amanda Mather Australia 8 506 2.2× 274 1.7× 270 2.1× 43 0.5× 44 0.7× 22 804
Jung Yeon Ghee South Korea 14 76 0.3× 160 1.0× 102 0.8× 37 0.4× 70 1.1× 32 696

Countries citing papers authored by F. Ravandi Kashani

Since Specialization
Citations

This map shows the geographic impact of F. Ravandi Kashani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Ravandi Kashani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Ravandi Kashani more than expected).

Fields of papers citing papers by F. Ravandi Kashani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Ravandi Kashani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Ravandi Kashani. The network helps show where F. Ravandi Kashani may publish in the future.

Co-authorship network of co-authors of F. Ravandi Kashani

This figure shows the co-authorship network connecting the top 25 collaborators of F. Ravandi Kashani. A scholar is included among the top collaborators of F. Ravandi Kashani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Ravandi Kashani. F. Ravandi Kashani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Steven, Sebastian, Matthias Oelze, Michael Hausding, et al.. (2018). The Endothelin Receptor Antagonist Macitentan Improves Isosorbide‐5‐Mononitrate (ISMN) and Isosorbide Dinitrate (ISDN) Induced Endothelial Dysfunction, Oxidative Stress, and Vascular Inflammation. Oxidative Medicine and Cellular Longevity. 2018(1). 7845629–7845629. 12 indexed citations
3.
Hanf, Alina, Sebastian Steven, Matthias Oelze, et al.. (2017). The SGLT2 Inhibitor Empagliflozin Improves the Primary Diabetic Complications in ZDF Rats. Free Radical Biology and Medicine. 112. 112–113. 6 indexed citations
4.
Steven, Sebastian, Matthias Oelze, Alina Hanf, et al.. (2017). The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biology. 13. 370–385. 243 indexed citations
5.
Steven, Sebastian, Mobin Dib, Michael Hausding, et al.. (2017). CD40L controls obesity-associated vascular inflammation, oxidative stress, and endothelial dysfunction in high fat diet-treated and db/db mice. Cardiovascular Research. 114(2). 312–323. 41 indexed citations
6.
Steven, Sebastian, Mobin Dib, Siyer Roohani, et al.. (2017). Time Response of Oxidative/Nitrosative Stress and Inflammation in LPS-Induced Endotoxaemia—A Comparative Study of Mice and Rats. International Journal of Molecular Sciences. 18(10). 2176–2176. 29 indexed citations
7.
Steven, Sebastian, Kerstin Jurk, Maximilian Kopp, et al.. (2016). Glucagon‐like peptide‐1 receptor signalling reduces microvascular thrombosis, nitro‐oxidative stress and platelet activation in endotoxaemic mice. British Journal of Pharmacology. 174(12). 1620–1632. 83 indexed citations
8.
Mikhed, Yuliya, Jörg Fahrer, Matthias Oelze, et al.. (2016). Nitroglycerin induces DNA damage and vascular cell death in the setting of nitrate tolerance. Basic Research in Cardiology. 111(4). 11 indexed citations
9.
O’Brien, Susan, S. Faderl, F. Ravandi Kashani, et al.. (2010). Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL).. Journal of Clinical Oncology. 28(15_suppl). 6506–6506. 28 indexed citations
10.
Kantarjian, H., Susan O’Brien, F. Ravandi Kashani, et al.. (2010). Phase II study of hyper-CVAD followed by nelarabine consolidation in newly diagnosed patients with T cell acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL).. Journal of Clinical Oncology. 28(15_suppl). 6524–6524. 1 indexed citations
11.
Dean, Andrew, Moshe Talpaz, H. Kantarjian, et al.. (2010). Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignancies.. Journal of Clinical Oncology. 28(15_suppl). 6549–6549. 15 indexed citations
12.
Stuart, Robert K., F. Ravandi Kashani, Larry D. Cripe, et al.. (2010). Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules.. Journal of Clinical Oncology. 28(15_suppl). 6525–6525. 11 indexed citations
13.
14.
Kashani, F. Ravandi, Jan Trøst Jørgensen, Stefan Faderl, et al.. (2010). Randomized study of decitabine versus conventional care (CC) in patients (pts) with intermediate- and high-risk acute myeloid leukemia (AML) in first or subsequent complete remission (CR).. Journal of Clinical Oncology. 28(15_suppl). 6527–6527. 1 indexed citations
15.
Borthakur, G., Elias Jabbour, Jörge E. Cortes, et al.. (2010). Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML).. Journal of Clinical Oncology. 28(15_suppl). 6552–6552. 4 indexed citations
16.
Kashani, F. Ravandi, Jörge E. Cortes, Stefan Faderl, et al.. (2009). Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML). Journal of Clinical Oncology. 27(15_suppl). 7018–7018. 2 indexed citations
17.
Kashani, F. Ravandi, et al.. (2004). THE RELATION BETWEEN ASYMPTOMATIC BACTERIURIA AND PREECIAMPSIA. Majallah-i dānishgāh-i ̒ulūm-i pizishkī-i Gurgān.. 6(13). 56–61. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leonardo Gómez Rosso Breakdown of academic impact, for papers by Shenghua Yang Breakdown of academic impact, for papers by Tomoe Kinoshita Breakdown of academic impact, for papers by Abdolrahim Nikzamir Breakdown of academic impact, for papers by Leena E. Viiri Breakdown of academic impact, for papers by S. Takami Breakdown of academic impact, for papers by Keiichi Torimoto Breakdown of academic impact, for papers by Mizuko Osaka Breakdown of academic impact, for papers by Amanda Mather Breakdown of academic impact, for papers by Jung Yeon Ghee
Rankless by CCL
2026